NASDAQ:AUGX Augmedix (AUGX) Stock Price, News & Analysis $2.27 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.27▼$2.2850-Day Range$0.75▼$2.2752-Week Range$0.73▼$6.25Volume277,062 shsAverage Volume742,878 shsMarket Capitalization$111.16 millionP/E RatioN/ADividend YieldN/APrice Target$3.09 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Augmedix alerts: Email Address Augmedix MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside36.0% Upside$3.09 Price TargetShort InterestHealthy3.61% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.21Based on 16 Articles This WeekInsider TradingSelling Shares$10,753 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.72 out of 5 starsMedical Sector268th out of 936 stocksBusiness Services, Not Elsewhere Classified Industry43rd out of 93 stocks 4.0 Analyst's Opinion Consensus RatingAugmedix has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageAugmedix has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Augmedix's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.61% of the float of Augmedix has been sold short.Short Interest Ratio / Days to CoverAugmedix has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Augmedix has recently decreased by 15.69%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAugmedix does not currently pay a dividend.Dividend GrowthAugmedix does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AUGX. Previous Next 2.9 News and Social Media Coverage News SentimentAugmedix has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Augmedix this week, compared to 2 articles on an average week.Search Interest7 people have searched for AUGX on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.MarketBeat Follows2 people have added Augmedix to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Augmedix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,753.00 in company stock.Percentage Held by Insiders10.97% of the stock of Augmedix is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions87.11% of the stock of Augmedix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Augmedix's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Augmedix is -5.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Augmedix is -5.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAugmedix has a P/B Ratio of 4.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Augmedix's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."Click here to see why Wall Street is in PANIC mode >>> About Augmedix Stock (NASDAQ:AUGX)Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits. The company enables clinicians to access its applications through mobile devices, such as smartphones. It serves health systems and specialty groups. The company was founded in 2013 and is headquartered in San Francisco, California.Read More AUGX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AUGX Stock News HeadlinesJuly 25 at 8:53 AM | msn.comIs Augmedix, Inc. (AUGX) the Best One-Dollar Stock to Buy Right Now?July 23, 2024 | markets.businessinsider.comMaintaining Hold Rating for Augmedix Amidst Acquisition and Challenging Financial OutlookJuly 27, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.July 23, 2024 | finance.yahoo.comCommure signs agreement to acquire Augmedix in $139m dealJuly 23, 2024 | americanbankingnews.comAugmedix (NASDAQ:AUGX) Downgraded by William Blair to HoldJuly 23, 2024 | americanbankingnews.comAugmedix's (AUGX) "Hold" Rating Reaffirmed at Lake Street CapitalJuly 23, 2024 | americanbankingnews.comMoneyHero (NASDAQ:MNY) & Augmedix (NASDAQ:AUGX) Critical ComparisonJuly 20, 2024 | benzinga.comCrude Oil Down 3%; Netflix Earnings Top EstimatesJuly 27, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.July 20, 2024 | americanbankingnews.comAugmedix (NASDAQ:AUGX) Downgraded by B. Riley to HoldJuly 19, 2024 | investorplace.comWhy Is Augmedix (AUGX) Stock Up 150% Today?July 19, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Augmedix, Inc. has obtained a Fair Price for its Public ShareholdersJuly 19, 2024 | globenewswire.comAugmedix to Join Forces with CommureJune 20, 2024 | globenewswire.comEmergency Services Inc. Partners with Augmedix to Introduce Generative AI Solution That Relieves Clinician Burnout in Emergency DepartmentsJune 4, 2024 | globenewswire.comAugmedix Reiterates Second Quarter and Full Year 2024 OutlookMay 29, 2024 | globenewswire.comAugmedix Appoints Alex Stinard, M.D., as Chief Clinical AI OfficerMay 15, 2024 | benzinga.comLatest News for Augmedix Stock (NASDAQ:AUGX)May 14, 2024 | finanznachrichten.deAugmedix Inc: Augmedix Delivers 40% Revenue Growth for First Quarter of 2024See More Headlines Receive AUGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Augmedix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Business services, not elsewhere classified Sub-IndustryN/A Current SymbolNASDAQ:AUGX CUSIPN/A CIK1769804 Webwww.augmedix.com Phone888-669-4885FaxN/AEmployees1,430Year FoundedN/APrice Target and Rating Average Stock Price Target$3.09 High Stock Price Target$5.00 Low Stock Price Target$1.50 Potential Upside/Downside+36.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,170,000.00 Net Margins-41.95% Pretax Margin-41.89% Return on Equity-178.34% Return on Assets-38.74% Debt Debt-to-Equity Ratio0.73 Current Ratio2.04 Quick Ratio2.04 Sales & Book Value Annual Sales$44.85 million Price / Sales2.48 Cash FlowN/A Price / Cash FlowN/A Book Value$0.56 per share Price / Book4.05Miscellaneous Outstanding Shares48,970,000Free Float43,596,000Market Cap$111.16 million OptionableOptionable Beta-0.27 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Emmanuel Krakaris (Age 65)President, CEO, Secretary & Director Comp: $734.33kMr. Ian Shakil (Age 39)Founder, Chief Strategy Officer & Director Ms. Sandra Breber (Age 66)Chief Operating Officer Comp: $446.05kMr. Saurav Chatterjee Ph.D. (Age 52)Chief Technology Officer Comp: $438.05kMr. Paul Louis Ginocchio (Age 54)Chief Financial Officer Todd HolvickHead of Legal & ComplianceLia WallickHead of PeopleDr. Davin Lundquist M.D.Chief Medical OfficerMr. Jonathan Hawkins (Age 54)Chief Revenue Officer Comp: $417.71kMr. Tomer LevySenior Vice President of EngineeringMore ExecutivesKey CompetitorsResources ConnectionNASDAQ:RGPZhihuNYSE:ZHAccoladeNASDAQ:ACCDMultiPlanNYSE:MPLNSpree Acquisition Corp. 1NYSE:SHAPView All CompetitorsInsiders & InstitutionsBoston PartnersBought 54,372 shares on 5/28/2024Ownership: 0.283%Ancora Advisors LLCBought 225,330 shares on 5/16/2024Ownership: 0.908%Kennedy Capital Management LLCSold 28,564 shares on 5/16/2024Ownership: 0.757%FourWorld Capital Management LLCBought 50,515 shares on 5/16/2024Ownership: 0.103%Paul GinocchioSold 2,354 sharesTotal: $2,801.26 ($1.19/share)View All Insider TransactionsView All Institutional Transactions AUGX Stock Analysis - Frequently Asked Questions How have AUGX shares performed this year? Augmedix's stock was trading at $5.85 at the beginning of 2024. Since then, AUGX shares have decreased by 61.2% and is now trading at $2.27. View the best growth stocks for 2024 here. How were Augmedix's earnings last quarter? Augmedix, Inc. (NASDAQ:AUGX) released its quarterly earnings results on Monday, May, 13th. The company reported ($0.12) earnings per share for the quarter, hitting the consensus estimate of ($0.12). The company earned $13.47 million during the quarter, compared to analysts' expectations of $13.25 million. Augmedix had a negative net margin of 41.95% and a negative trailing twelve-month return on equity of 178.34%. When did Augmedix IPO? Augmedix (AUGX) raised $40 million in an initial public offering (IPO) on Tuesday, October 26th 2021. The company issued 10,000,000 shares at a price of $4.00 per share. William Blair, B. Riley Securities, Benchmark and Lake Street served as the underwriters for the IPO. How do I buy shares of Augmedix? Shares of AUGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AUGX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Augmedix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Augmedix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
